CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG would like to say congratulations to our colleagues Ian Tannock and Natasha Leighl both from the Princess Margaret Cancer Centre for their recent recognition by ASCO as 2019 Leaders in Cancer Care
Allen S. Lichter Visionary Leader Award and Lecture
This award was created in honor of Allen. S. Lichter, MD, FASCO, to recognize ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, the Conquer Cancer Foundation, or CancerLinQ, LLC, through their leadership, vision, and ability to inspire.
We are very saddened to share that our esteemed colleague Dr. Stephen Couban passed away on March 19, 2019 at his home in Halifax.
Stephen was a remarkable leader, everyone at CCTG and across the network are grateful for the years of leadership he provided as the Co-Chair of the Hematology Disease Site Committee and Chair of the Leukemia Subcommittee.
The Canadian Cancer Trials Group 2019 Annual Spring Meeting will be held May 3 - 5, 2019 at the Chelsea Hotel in Toronto. Invitations have been sent and it is now time for you to register!
The CCTG Lay Representatives Committee has been renamed the Patient Representatives Committee.
Former cancer patient, Judy Needham is the Chair of the Canadian Cancer Trials Group (CCTG) Patient Representatives Committee (formerly Lay Committee). She talks about the role of the patient voice in the development of clinical trials. Before partnering with CCTG, Judy was a board member of the former BC chapter of the Canadian Breast Cancer Foundation, championing the first Breast Cancer Navigation Map, a patient tool aimed at simplifying the breast cancer journey. Since 2012, Ms.
Dr Daniel Renouf is the pancreatic cancer disease site chair and in this interview he discusses the PA7 trail which explores whether adding immunotherapy to chemotherapy can improve the efficacy or the positive effects of treatment for patients
600 PATIENTS RANDOMIZED!!!
Congratulations to Dr. Willibald Schroeder and the team at GYNAEKOLOGICUM Bremen, Germany for enrolling the 600th patient to the SHAPE study! On behalf of the SHAPE trial committee, we would like to thank you for your tremendous and unwavering support of our trial. The countdown is on....let's see the SHAPE trial reach its accrual goal by the end of 2019!
